Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.